Drug details

Ontruzant (trastuzumab-dttb for injection)

type of Antineoplastics, Anti-HER2

Ontruzant (trastuzumab-dttb) is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

This drug may have the following side effects:

• shortness of breath,
• dizziness,
• sore throat,
• fever,
• swelling,
• fatigue
• hives, 
• difficulty breathing, 
• swelling of your face, lips, tongue, or throat, 
• fatigue,
• chest pain or pressure, 
• chills, and

The following drugs are related to Ontruzant, either as a replacement or used together:

• Afinitor (everolimus tablets)
• Arimidex (anastrozole)
• Aredia (pamidronate disodium)
• Halaven Injection (eribulin mesylate)
• Femara (letrozole)
• Herceptin (trastuzumab)
• Ixempra (ixabepilone)
• Kisqali (ribociclib tablets)
• Kisqali FeMara Co-Pack (ribociclib and letrozole tablets)
• Nolvadex (tamoxifen citrate)
• Perjeta (pertuzumab)
• Soltamox (tamoxifen citrate)
• Tukysa (tucatinib tablets)